// App-Quantinova.ai

330 : The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results

Researchers

Presenter

  • David A. Sallman

Principal Investigators

  • Suman Kambhampati

  • Monzr M. Al Malki

  • Joshua F. Zeidner

  • William Donnellan

  • Daniel J. Lee

  • Paresh Vyas

  • Deepa Jeyakumar

  • Gabriel N. Mannis

  • Tiffany N Tanaka

  • Wanxing Chai-Ho

  • Richard A. Larson

  • Andrew R. Whiteley

  • Guido Marcucci

  • Rami S. Komrokji

  • Guillermo Garcia-Manero

  • Joanna Van Elk

  • Ming Lin

  • Roy Maute

  • Jens-Peter Volkmer

  • Chris H. Takimoto

  • Mark P. Chao

  • Naval Daver

Medical Centers

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Stephenson Cancer Center/The University of Oklahoma Health Sciences Center, Oklahoma City, OK.

  • HCA Midwest Health at Research Medical Center, Kansas City, MO

  • City of Hope, Duarte, CA

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

  • Tennessee Onc/Sarah Cannon Rsrch Inst, Nashville, TN

  • Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY

  • University of Oxford, Oxford, United Kingdom

  • University of California Irvine Health Chao Family Comprehensive Cancer Center, Orange, CA

  • Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA

  • Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Orange, CA

  • Department of Medicine, Section of Hematology and Oncology, The University of Chicago, Chicago, IL

  • Baylor University Medical Center, Dallas, TX

  • 1.MD Anderson Cancer Center, Houston, TX

  • Gilead Sciences, Inc., Foster City, CA

Locations

  • United States

  • United Kingdom

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • Vidaza

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT03248479

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved